Medtronic 2015 Annual Report Download - page 100

Download and view the complete annual report

Please find page 100 of the 2015 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 166

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166

Medtronic plc
Notes to Consolidated Financial Statements (Continued)
During fiscal year 2014, the Company recorded certain litigation charges, net of $770 million, which primarily includes the
global patent settlement agreement with Edwards Lifesciences Corporation (Edwards) of $589 million, accounting charges for
probable and reasonably estimable INFUSE product liability litigation of $140 million, and other litigation.
During fiscal year 2013, the Company recorded certain litigation charges, net of $245 million related to probable and reasonably
estimated damages related to the patent litigation with Edwards.
5. Investments
The Company holds investments consisting primarily of marketable debt and equity securities.
Information regarding the Company’s investments at April 24, 2015 is as follows:
(in millions) Cost
Unrealized
Gains
Unrealized
Losses Fair Value
Available-for-sale securities:
Corporate debt securities $ 6,283 $ 105 $ (10) $ 6,378
Auction rate securities 109 — (4) 105
Mortgage-backed securities 1,462 22 (6) 1,478
U.S. government and agency securities 3,122 21 (4) 3,139
Foreign government and agency securities 85——85
Certificates of deposit 44——44
Other asset-backed securities 504 3 — 507
Debt funds 3,061 19 (150) 2,930
Marketable equity securities 64 35 (19) 80
Trading securities:
Exchange-traded funds 58 19 — 77
Cost method, equity method, and other investments 520 — — NA
Total investments $ 15,312 $ 224 $ (193) $ 14,823
Information regarding the Company’s investments at April 25, 2014 is as follows:
(in millions) Cost
Unrealized
Gains
Unrealized
Losses Fair Value
Available-for-sale securities:
Corporate debt securities $ 5,504 $ 55 $ (17) $ 5,542
Auction rate securities 109 — (12) 97
Mortgage-backed securities 1,337 7 (8) 1,336
U.S. government and agency securities 3,138 7 (29) 3,116
Foreign government and agency securities 67——67
Certificates of deposit 54——54
Other asset-backed securities 540 2 — 542
Debt funds 2,143 9 (29) 2,123
Marketable equity securities 47 15 (13) 49
Trading securities:
Exchange-traded funds 54 13 — 67
Cost method, equity method, and other investments 666 — — NA
Total investments $ 13,659 $ 108 $ (108) $ 12,993
90